ThromboGenics

Companies ThromboGenics

News ThromboGenics

• European Medicines Agency recommends approval of medicine for treatment of vitreomacular traction

  The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Jetrea, a medicinal product indicated for the treatment of adults with vitreomacular traction (VMT), an eye condition which can cause severe visual disturbance. Jetrea re more

• ThromboGenics and BioInvent Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402

  ThromboGenics NV and co-development partner BioInvent International announced the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban (Xarelto®; Bayer), an oral anticoagulant.  The study showed that the incidence of venous thromboembolism (VTE) was simil more

• ThromboGenics Opens New U.S. Headquarters

  ThromboGenics NV announced the opening of its new U.S headquarters. The facility which is situated in Iselin, New Jersey, is the new home to the Company’s U.S. organization which is led by Dr. David Pearson, Head of U.S. Country Operations. ThromboGenics has been growing its U.S. team in recent mont more

Market studies ThromboGenics

• Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Diabetic Retinopathy (DR) therapeutics market. more

• Ophthalmic Drugs: World Market 2011-2021

  Where will the highest revenue growth occur in the ophthalmic drug market? Our new report shows you the eye disorder treatment market's potential from 2011 to 2021. We forecast and explain the commercial opportunities there. Our report gives you revenue predictions for ophthalmic treatments from 20 more

• ThromboGenics NV (THR) - Financial and Strategic SWOT Analysis Review

  ThromboGenics NV (THR) - Financial and Strategic SWOT Analysis Review Summary ThromboGenics NV (ThromboGenics) is a biopharmaceutical company engaged in the discovery and development of therapeutics for the treatment of diseases related to the eye, blood-vessels and cancer. The company's product p more

Websites ThromboGenics